|
|
Article: Study Shows More Potent and More Reliable Platelet Inhibition with Prasugrel Compared to Clopidogrel Even in Patients With More Reactive Platelets.
- Article from:
- PR Newswire
- Article date:
- March 14, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
INDIANAPOLIS and TOKYO, March 14 /PRNewswire-FirstCall/ -- In early phase data announced today, the investigational antiplatelet agent, prasugrel, demonstrated greater and more reliable antiplatelet effect compared to clopidogrel (Plavix(R)) even in patients with increased platelet reactivity. These data were featured in one of several prasugrel presentations at the 2006 Scientific Sessions of the American College of Cardiology in Atlanta.
In a Phase Ib study, greater than 90 percent of prasugrel-treated patients achieved greater than 20 percent inhibition of platelet aggregation (IPA), compared with less than 50 percent of clopidogrel-treated patients. The ...